

## Seizures in Drug-Treated Animals

In a recent article in the Research News section (5 Dec., p. 1198), Gina Kolata highlights important new results with a novel benzodiazepine derivative, especially its capacity to reverse the intoxicating effects of alcohol. This new substance, an imidazo-benzodiazepine identified as Ro15-4513, is reported to (i) "make . . . drunk animals behave as though they were sober," (ii) "block . . . the behavioral effects of alcohol intoxication," (iii) prevent animals from "act[ing] intoxicated in the first place," and (iv) "appear to have no ill effects on the animals." In addition a photograph shows one rat "passed out from alcohol intoxication" and a second rat that "acted sober" after it was given Ro15-4513. Some of the most significant statements of this article concern the safety of Ro15-4513. Repeatedly, the article suggests that Ro15-4513 is without adverse or "ill" effects, "much less risky," and "safe."

In the same issue of *Science*, Suzdak *et al.* (Reports, p. 1243) state that "in contrast to other benzodiazepine receptor inverse agonists, Ro15-4513 alone at doses as high as 10 milligrams per kilogram of body weight produced no overt behavioral actions." Two types of behavioral measurements were performed in this project: (i) the number of licks on a water spout was counted, when every fifth lick produced an 0.4 milliamper electric shock [this measurement is widely used as a preclinical screen for drugs with anxiolytic properties (1)]; and (ii) ratings were made by an observer on a seven-point scale for 6 to 10 minutes assessing the magnitude of alcohol intoxication (2). Both measurements were conducted in laboratory rats of the Sprague-Dawley strain.

In our experiments with Ro15-4513 in rats and in squirrel monkeys, conducted during the past 4 months, we have found potentially serious side effects that may compromise the usefulness of Ro15-4513 as a drug that "counters alcohol intoxication." The most important detrimental effects of Ro15-4513 were evident in our experiments with adult male squirrel monkeys (*Saimiri sciureus*) housed as members of four social groups (3). Administration of Ro15-4513 (1 milligram per kilogram orally) produced severe tremors in seven out of eight monkeys; in two monkeys clear behavioral and physiological signs of convulsive activity, including tonic and clonic phases, were seen. The monkeys were observed to show muscular rigidity and posturing of the limbs, followed by repetitive contractions of so-

matic musculature. Since none of the information available to us led us to expect any such effects, we were not prepared to record electroencephalographic activity during our behavioral experiments. However, like others, we have not seen any such convulsive effects in our studies with rats.

Intrinsic behavioral effects of Ro15-4513 were evident in our experiments with both squirrel monkeys and rats (4). Briefly, disruption of social and aggressive behavior occurred in both species after administration of Ro15-4513 (1 milligram per kilogram by intraperitoneal injection in rats, orally in squirrel monkeys) in the absence of ethanol. The frequency of associative, threat, and attack behavior decreased by 60% to 80% from vehicle control levels. In view of these large changes it appears premature to refer to Ro15-4513 as having "no behavioral actions." However, in confirmation of the observations by Suzdak *et al.* we also recorded a partial restoration of motor activity that was impaired by large alcohol doses (1.5 to 3.0 grams per kilogram orally) in both rats and squirrel monkeys.

Our observations emphasize the necessity to conduct preclinical studies in primates in addition to laboratory rodents. Careful quantitative ethological measurements are required for an adequate assessment of the behavioral specificity and safety of therapeutically promising drugs.

KLAUS A. MICZEK  
ELISE M. WEERTS

Department of Psychology,  
Tufts University,  
Medford, MA 02155

## REFERENCES

1. J. R. Vogel, B. Beer, D. E. Clody, *Psychopharmacologia* **21**, 1 (1979).
2. E. Majchrowicz, *ibid.* **43**, 245 (1975).
3. K. A. Miczek and L. H. Gold, *ibid.* **81**, 183 (1983); J. T. Winslow and K. A. Miczek, *ibid.* **85**, 167 (1985).
4. K. A. Miczek and E. M. Weerts, in preparation.

**Response:** Miczek and Weerts point out that Ro15-4513 has intrinsic behavioral actions in rats and squirrel monkeys that may limit its use as a potential alcohol antagonist in man. This conclusion has already been made by both research groups who have published data concerning the alcohol-blocking actions of this drug (1). Kolata's article deals primarily with the use of Ro15-4513 as a research tool and the pros and cons of developing a clinically effective "derivative or analogue" based on the behavioral and biochemical findings with Ro15-4513.


Since Ro15-4513 is a partial inverse agonist of the benzodiazepine receptor, as emphasized and cited in our report (p. 1244) as well as in the previous publications about this compound (2-5), it would be expected

(and has already been reported) to have intrinsic pharmacological actions, including "anxiogenic" and proconvulsant effects. For this reason we administered Ro15-4513 in the conflict test at doses that did not significantly decrease the number of either punished or nonpunished responses; at these doses Ro15-4513 blocked the anticonflict effects of ethanol. At higher doses [or under different behavioral parameters (for example, shock intensity or amount of water deprivation)] Ro15-4513, like other inverse agonists, would be expected to decrease punished or nonpunished responses, or both (6), and would therefore appear to "antagonize" any drug that increases the number of punished responses, including pentobarbital. We would also like to emphasize that with the use of different behavioral tests, Ro15-4513 has been reported to antagonize the actions of barbiturates (2, 3). The observation of Miczek and Weerts that Ro15-4513 disrupts social and aggressive behaviors in more "naturalistic" behavioral paradigms confirms previous reports on other inverse agonists (7). Moreover, that Ro15-4513 has no convulsant effects in rats (which confirms our report of no overt or easily observable behavioral actions of Ro15-4513 in this species), but has tremorigenic and convulsive activity in squirrel monkeys, is consistent with previous studies on other inverse agonists reported by several groups (8). Schwenker *et al.* (9) have shown, for example, that  $\beta$ -carboline carboxylate ethyl ester does not produce seizures in rats but is a potent convulsant in squirrel monkeys, a phenomenon that appears to be related to the differential metabolism of the labile ester moiety in rats and monkeys. Pharmacokinetic and pharmacodynamic differences between species have always been a major consideration in drug development.

As we pointed out to Kolata (p. 1198), Ro15-4513 is only a prototype. A clinically effective compound should be "a long-acting derivative" (ideally with a half-life greater than ethanol) devoid of "adverse effects" including those expected of a partial inverse agonist. The ability of Ro15-4513 to reverse or block many (but not all) of alcohol's behavioral effects, however, does not appear to be attributable to its inverse agonist properties, since in both our experiments and those of Bonetti *et al.* (2) and of Polc *et al.* (3), other partial or full inverse agonists tested either did not attenuate or only slightly attenuated alcohol's behavioral, biochemical, and electrophysiological actions. Thus, on the basis of the available biochemical and behavioral data, it appears that the inverse agonist and alcohol antagonist properties of benzodiazepine receptor ligands are dissociable, which makes the development of an

## PIPETTING? SINGLE-SHOT MICROLITER DISPENSING?

**Try the all-new  
FMI  
micro  $\pi$ -petter!**



It provides a simple, low-cost means of dispensing very small amounts of fluids for applications such as pipetting, reagent preparation, syringing, precision sampling, repetitive and volumetric dispensing. The variable displacement, valveless RR piston design makes it possible to dispense volumes of 2 to 100  $\mu$ l per shot with incremental adjustment of less than 0.5  $\mu$ l. PiP units are also reversible for aspirating fluids or back flushing the system.

A simple, sealed pushbutton hand/foot pendant switch makes a momentary contact for one dispense per push when the mode switch is in the down (Singles) position, or it may be held down for purging or reagent rinsing when the mode switch is in the up (Repeat) position. Using a combination of forward and reverse modes makes dilutions especially easy. Wetted surfaces of ceramic and fluorocarbon provide for maximum chemical compatibility. A three-speed 110 VAC 60 Hz synchronous motor provides three shot velocities to meet your fluid and vessel requirements.

Two standard models are available at a price of \$450 each. F.O.B. FMI:  
Model PiPOCKC—0 to 50  $\mu$ l;  
Model PiPICKC—0 to 100  $\mu$ l.

Available for same day shipment.

**FMI FLUID METERING, INC.**

P.O. Box 179  
29 Orchard St., Oyster Bay, NY 11771  
516-922-6050 • Telex 5101001281

See us at the Pittsburgh Conference: Booth 922/924

Circle No. 74 on Readers' Service Card

## REFBASE™

An affordable, full-function reference program!

- Uses DBase\* compatible files (DBase II or DBase III). Appends records from files downloaded from BRS Colleague and Medline.
- Uses easy single key stroke operation. Great for the beginner or the advanced user.
- Places references in manuscripts by name or number. Generates bibliography in style of your choice.
- Designed for the IBM PC or a compatible system with 256 KB or more of RAM.
- Complete REFBASE system, including all modules and documentation, is only \$125.
- A demo disc is available for only \$4.

For more details, write or call:

DataChip Corporation  
5624 Pierce St., Omaha, NE 68106  
(402) 553-4333

**DataChip**

\*DBase is a trademark of Ashton-Tate

Circle No. 96 on Readers' Service Card

## AUTOMATE MEASUREMENT ON YOUR IBM PC



Photo Courtesy/Edward Jones, M.D.

New digitizing tablet with  
Sigma-Scan™ measurement  
software. \$1195

Cat #3011 — 12" x 12" system

Resolution of .025 mm, accuracy of at least .25 mm. Comes with state-of-the-art software for area, linear, perimeter, length of curvy line, and angular measurements. X, Y point or stream digitizing. Descriptive statistics. Transfer data to other programs in standard ASCII or DIF format.

Call or write today for more information.

**JANDEL SCIENTIFIC**

MICROCOMPUTER TOOLS FOR THE SCIENTIST  
2656 Bridgeway, Sausalito, CA 94965  
800-874-1888

(In Calif. call 415-331-3022)

Circle No. 136 on Readers' Service Card

alcohol antagonist devoid of discernible side effects a possibility. It will be interesting to see whether the actions of Ro15-4513 in reversing alcohol's sedative actions in primates as reported by Miczek and Weerts are observed with other inverse agonists. Finally, Miczek and Weerts confirm our findings in rats that Ro15-4513 will "partially restore motor activity that was impaired by large alcohol doses (1.5 to 3.0 grams per kilogram orally)" and extend these observations to squirrel monkeys. We would like to emphasize that in our studies in rats Ro15-4513 is more potent at blocking the intoxication syndrome (that is, when administered before alcohol) than in reversing it, since the latter requires higher doses of drug (10). Ro15-4513 promises to remain an important tool in alcohol research as we and others attempt to develop analogues that are more efficacious and devoid of inverse agonist properties.

PETER D. SUZDAK\*

JOHN R. GLOWA\*

JACQUELINE N. CRAWLEY\*

ROCHELLE D. SCHWARTZ\*

PHIL SKOLNICK†

STEVEN M. PAUL\*

\*Clinical Neuroscience Branch,  
National Institute of Mental Health,  
Bethesda, MD 20892, and

†Section on Neurobiology,  
Laboratory of Bioorganic Chemistry,  
National Institute of Diabetes and Digestive  
and Kidney Diseases,  
Bethesda, MD 20892

### REFERENCES AND NOTES

1. G. Kolata, *Science* **234**, 1198 (1986); Associated Press, *New York Times*, 28 November 1986, p. A23; J. Hammer, *Esquire* **106** (No. 6), 218 (December 1986).
2. E. P. Bonetti, W. P. Burkard, M. Gabl, H. Mohler, *Br. J. Pharmacol.* **86**, 463P (1985).
3. P. Polc *et al.*, *ibid.*, p. 465P.
4. P. D. Suzdak *et al.*, *Science* **234**, 1243 (1986).
5. H. Mohler, W. Sieghart, J. G. Richards, W. Hunziker, *Eur. J. Pharmacol.* **102**, 191 (1984); W. Sieghart, A. Eichinger, J. G. Richards, H. Mohler, *J. Neurochem.* **48**, 46 (1987).
6. M. Corda, W. Blaker, W. Mendelson, A. Guidotti, E. Costa, *Proc. Natl. Acad. Sci. U.S.A.* **80**, 2072 (1983); J. R. Glowa, P. Skolnick, S. M. Paul, *Eur. J. Pharmacol.* **129**, 39 (1986).
7. S. E. File, in *Pharmacology of Benzodiazepines*, E. Usdin, P. Skolnick, J. Tallman, D. Greenblatt, S. M. Paul, Eds. (Macmillan, London, 1982), pp. 355-364; P. Skolnick, G. Reed, S. M. Paul, *Pharmacol. Biochem. Behav.* **23**, 17 (1985).
8. N. R. Oakley and B. J. Jones, *Neuropharmacology* **21**, 587 (1982); C. Braestrup, R. Schmiechen, G. Neff, M. Nielsen, E. Peterson, *Science* **216**, 1241 (1982).
9. M. Schwenk *et al.*, *Life Sci.* **33**, 1505 (1983).
10. P. D. Suzdak, S. M. Paul, J. N. Crawley, in preparation.

**Erratum:** In the Technical Comment "Trans-activator gene of HTLV-II: Interpretation" by W. C. Greene *et al.* (27 Feb., p. 1073), the third-from-the-last sentence should have read, "In addition, using Jurkat or other T-cell lines, Inoue and colleagues (2) and Maruyama *et al.* (3) have described activation of both the IL-2 receptor and IL-2 genes by the *tax*-I gene isolated from HTLV-I, which shares similar structural and functional properties with the *tax*-II gene." Reference 3 should have been to M. Maruyama *et al.*, *Cell* **48**, 343 (1987).

SCIENCE, VOL. 235